| Literature DB >> 24904533 |
Anton G Kutikhin1, Arseniy E Yuzhalin2, Vadim V Borisov3, Elena A Velikanova3, Alexey V Frolov3, Vera M Sakharova3, Elena B Brusina4, Alexey S Golovkin3.
Abstract
Entities:
Keywords: atherosclerosis; calcification; calcifying nanoparticles; diseases; hydroxyapatite; inflammation; nanobacteria; nanobacteria-like particles
Year: 2014 PMID: 24904533 PMCID: PMC4033009 DOI: 10.3389/fmicb.2014.00214
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Properties of calcifying nanoparticles (CNPs).
| Morphological properties | 80–500 nm in diameter (can pass through 100-nm filters) |
| Usually have coccoid, coccobacillar, or bacillar form, often remind mineralized «igloo» | |
| Have hydroxyapatite shell, cellular-membranous structure, and central cavity | |
| Can form microscopic colonies (>1 mm in diameter) under the low concentration of nutrients in the environment | |
| Divide by binary fission, fragmentation, and gemmation | |
| Can form thermoresistant biofilms | |
| Tinctorial properties | Gram-negative, can be stained by DNA-specific dyes (Hoechst 33258 at a concentration of 5 μg/ml during 50 min, propidium iodide, PicoGreen—they are specific after the filtration through 0.1–0.22 μm pores, staining after a demineralization is optimal), can be revealed by von Kossa staining, staining by 2% uranyl acetate (possibly with lead citrate) can detect specific mucus on the hydroxyapatite shell, in the mineralized state can be stained by alizarin red S, can be stained by phosphotungstic acid |
| Resistance and sensitivity | Resistant to 90°C heating during 1 h |
| Resistant to γ-irradiation up to 30 kGray | |
| Resistant to 5% NaCl solution | |
| In the mineralized state are resistant to lyzozyme, proteinase K, certain other proteinases, lipases, amylases, alkali, ultrasound, X-ray, detergents, and solvents | |
| Temperature under 37°C suppresses replication and prevents biofilms formation | |
| Resistant to wide spectrum of antimicrobial therapeutics: aminoglycosides (in pharmacological concentrations), chloramphenicol, lincosamides, cephalosporins, macrolides, fluoroquinolones, glycopeptides (in pharmacological concentrations), polymyxins, antituberculous agents, aminocyclitol, spectinomycin | |
| Sensitive to tetracyclines, ampicillin, trimethoprim, trimethoprim-sulfamethoxazole, nitrofurantoin, 5-fluorouracil, cytosine arabinoside, antimycin A, sodium azide, potassium cyanide, bisphosphonates (etidronate, clodronate), 6-aminocaproic acid, | |
| Culture properties | Doubling time is 3 days, in media without serum—6 days |
| Passage can be performed in DMEM (Dulbecco's modified Eagle's medium) or RPMI-1640 independently of the presence of serum | |
| Optimal atmosphere for growth should contain 5% of CO2 and 95% of air | |
| Sensitive to β-mercaptoethanol, which stimulates growth of anaerobes, but cannot be cultivated under the strictly anaerobic conditions | |
| Calcify when serum concentration in the culture media is lower than 5% | |
| Cytotoxic for fibroblasts and lymphocytes | |
| Biochemical properties | Metabolism is 10,000 times slower than in |
| Incorporate uridine (into the expected nucleic acid), methionine, and aspartic acid (into the expected system of protein biosynthesis) | |
| Calcify under the physiological pH (7.4) | |
| Urease negative | |
| Detection methods | Bacterioscopic (DNA-specific dyes Hoechst 33258, propidium iodide, PicoGreen, staining after a demineralization is optimal) using scanning and transmission electron microscopy, von Kossa staining which is specific for calcium compounds, staining by 2% uranyl acetate (possibly with lead citrate) to detect specific mucus on the hydroxyapatite shell, staining by alizarin red S in the mineralized state, staining by phosphotungstic acid, after the long-term cultivation light microscopy with von Kossa staining is possible to be used for detection |
| Bacteriological (cultivation in DMEM or RPMI-1640 without serum under 37°C during 4–6 weeks after the filtration through 0.1–0.22 μm pores), replication can be assessed by spectrophotometry (650 nm wavelength) | |
| Serological CNP antigens and anti-CNP monoclonal antibodies 8/0 (to porin), 5/2 (to peptidoglycan) and 8D10 (to porin) of NanoBiotech Pharma, Tampa, FL, USA—ELISA, immunohistochemistry, immunofluorescence reaction, immunoblotting, Ouchterlony immunodiffusion | |
| Genomic (PCR), but there is doubt that existing primers are obtained on the basis of CNP nucleic acids, and not on the basis of nucleic acids of contaminating bacteria | |
| Proteomic (sodium dodecyl sulfate polyacrylamide gel electrophoresis with further identification of protein bands by mass spectrometry) | |
| Methods of treatment of CNP-associated diseases (atherosclerosis, heart valve calcification, placental calcification, nephrolithiasis, cholecystolithiasis, type III chronic prostatitis/chronic pelvic pain syndrome, and testicular microlithiasis) | comET-therapy (tetracycline, EDTA, and mix of nutrients) |
Abbreviations: CNPs, calcifying nanoparticles; EDTA, ethylenediaminetetraacetic acid; EGTA, ethyleneglycoltetraacetic acid; DMEM, Dulbecco's modified Eagle's medium; RPMI-1640, Roswell Park Memorial Institute 1640 medium; ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction. Cited from Chang et al. (.